Xiao-Guang Zhao

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Darell D. Bigner, Mark T. Brown, Allan H. Friedman et al. · Journal of Clinical Oncology · 1998 · 195 citations

Medicine, Nuclear Medicine, Oncology +14

A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

David A. Reardon, Michael R. Zalutsky, Gamal Akabani et al. · Neuro-Oncology · 2008 · 110 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Mark T. Brown, R. Edward Coleman, Allan H. Friedman et al. · PubMed · 1996 · 99 citations

Medicine, Nuclear Medicine, Oncology +16

Dosimetry and dose–response relationships in newly diagnosed patients with malignant gliomas treated with Iodine-131-Labeled anti-tenascin monoclonal antibody 81C6 therapy

Gamal Akabani, Ilkcan Cokgor, Robert E. Coleman et al. · International Journal of Radiation Oncology*Biology*Physics · 2000 · 69 citations

Medicine, Nuclear Medicine, Oncology +12

Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.

Gamal Akabani, Craig J. Reist, Ilkcan Cokgor et al. · PubMed · 1999 · 44 citations

Medicine, Nuclear Medicine, Oncology +15